Today, hosts Michael and Josh are joined by the wonderful Dr James McCracken to discuss highlights from ASCO 2025 in the areas of upper GI and hepatobiliary cancer. This episode focuses on two items that are (as Michael repetitively insists) "big ticket": MATTERHORN and Destiny-Gastric04. In addition, James gives his thoughts on studies that look at immunotherapy and novel neoadjuvant chemotherapy in pancreatic cancer, and a small study examining a perioperative approach to resectable biliary tract cancer.

Studies discussed in the episode:

MATTERHORN

Destiny-Gastric04

NeoIMPACT

CASSANDRA

GAIN

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.